Sector News

Shire and Baxalta near deal

January 4, 2016
Life sciences

Shire is reportedly in advanced talks to acquire Baxter’s biopharma spin-off Baxalta and may announce a deal this week.

According to Bloomberg, sources familiar with the matter have said that the Irish firm could buy Baxalta for $32 billion, or $46.50-$48 a share. The deal is expected to contain a cash component.

After Baxalta’s management rejected an initial bid, Shire went public with a $30 billion unsolicited offer in August 2015, only a month after Baxalta was spun off from Baxter.

After shareholders agreed with the board that this offer was too low, rumours swelled in November that Shire was looking to make a second approach and had asked its advisers to construct a new deal.

Flemming Ornskov, chief executive officer of Shire, has said that the companies could deliver $20 billion in product sales by 2020.

By George Underwood

Source: Pharma Times 

comments closed

Related News

October 2, 2022

GSK names Julie Brown, a 25-year AstraZeneca veteran, its first woman CFO

Life sciences

Five years ago, GSK made headlines when it hired Emma Walmsley to become the first woman to run a major pharmaceutical company. Now the Big Pharma has brought in another woman to control the company’s finances. Julie Brown will be GSK’s next chief financial officer. Brown, currently the chief operating and financial officer at fashion and beauty brand Burberry Group, is set to replace Iain Mackay.

October 2, 2022

Moderna creates new launch preparation role, poaches Novartis exec as manufacturing lead

Life sciences

Moderna created a new role responsible for “building out the company’s organization to support its growing pipeline.” Starting first thing 2023, Juan Andres, Moderna’s manufacturing head, will step into this new role under the title president of strategic partnerships and enterprise expansion, the company said Thursday.

October 2, 2022

Torrent Pharma to acquire Curatio for $245.16m

Life sciences

The latest takeover is anticipated to boost the presence of Torrent in the dermatology segment. Indian company Torrent Pharmaceuticals has signed a definitive agreement for the complete acquisition of Curatio Healthcare for $245.16m (Rs20bn).